Literature DB >> 28550191

The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma.

Sharmilan Thanendrarajan1, Erming Tian1, Pingping Qu1, Pankaj Mathur1, Carolina Schinke1, Frits van Rhee1, Maurizio Zangari1, Leo Rasche1, Niels Weinhold1, Daisy Alapat2, William Bellamy2, Cody Ashby1, Sandra Mattox1, Joshua Epstein1, Shmuel Yaccoby1, Bart Barlogie1, Antje Hoering3, Michael Bauer1, Brian A Walker1, Faith E Davies1, Gareth J Morgan4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28550191      PMCID： PMC5685226          DOI： 10.3324/haematol.2017.168872

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  The molecular classification of multiple myeloma.

Authors:  Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

2.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

Authors:  Hervé Avet-Loiseau; Michel Attal; Philippe Moreau; Catherine Charbonnel; Frédéric Garban; Cyrille Hulin; Serge Leyvraz; Mauricette Michallet; Ibrahim Yakoub-Agha; Laurent Garderet; Gérald Marit; Lucienne Michaux; Laurent Voillat; Marc Renaud; Bernard Grosbois; Gaelle Guillerm; Lotfi Benboubker; Mathieu Monconduit; Catherine Thieblemont; Philippe Casassus; Denis Caillot; Anne-Marie Stoppa; Jean-Jacques Sotto; Marc Wetterwald; Charles Dumontet; Jean-Gabriel Fuzibet; Isabelle Azais; Véronique Dorvaux; Marc Zandecki; Régis Bataille; Stéphane Minvielle; Jean-Luc Harousseau; Thierry Facon; Claire Mathiot
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

3.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

Authors:  John D Shaughnessy; Fenghuang Zhan; Bart E Burington; Yongsheng Huang; Simona Colla; Ichiro Hanamura; James P Stewart; Bob Kordsmeier; Christopher Randolph; David R Williams; Yan Xiao; Hongwei Xu; Joshua Epstein; Elias Anaissie; Somashekar G Krishna; Michele Cottler-Fox; Klaus Hollmig; Abid Mohiuddin; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Jeffrey Sawyer; Yazan Alsayed; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2006-11-14       Impact factor: 22.113

4.  Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.

Authors:  Maximilian Merz; Thomas Hielscher; Anja Seckinger; Dirk Hose; Elias K Mai; Marc S Raab; Hartmut Goldschmidt; Anna Jauch; Jens Hillengass
Journal:  Am J Hematol       Date:  2016-09-03       Impact factor: 10.047

5.  Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

Authors:  Antonio Palumbo; Hervé Avet-Loiseau; Stefania Oliva; Henk M Lokhorst; Hartmut Goldschmidt; Laura Rosinol; Paul Richardson; Simona Caltagirone; Juan José Lahuerta; Thierry Facon; Sara Bringhen; Francesca Gay; Michel Attal; Roberto Passera; Andrew Spencer; Massimo Offidani; Shaji Kumar; Pellegrino Musto; Sagar Lonial; Maria T Petrucci; Robert Z Orlowski; Elena Zamagni; Gareth Morgan; Meletios A Dimopoulos; Brian G M Durie; Kenneth C Anderson; Pieter Sonneveld; Jésus San Miguel; Michele Cavo; S Vincent Rajkumar; Philippe Moreau
Journal:  J Clin Oncol       Date:  2015-08-03       Impact factor: 44.544

6.  Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.

Authors:  Niels Weinhold; Cody Ashby; Leo Rasche; Shweta S Chavan; Caleb Stein; Owen W Stephens; Ruslana Tytarenko; Michael A Bauer; Tobias Meissner; Shayu Deshpande; Purvi H Patel; Timea Buzder; Gabor Molnar; Erich A Peterson; Frits van Rhee; Maurizio Zangari; Sharmilan Thanendrarajan; Carolina Schinke; Erming Tian; Joshua Epstein; Bart Barlogie; Faith E Davies; Christoph J Heuck; Brian A Walker; Gareth J Morgan
Journal:  Blood       Date:  2016-08-11       Impact factor: 22.113

7.  Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma.

Authors:  Y Jethava; A Mitchell; M Zangari; S Waheed; C Schinke; S Thanendrarajan; J Sawyer; D Alapat; E Tian; C Stein; R Khan; C J Heuck; N Petty; D Avery; D Steward; R Smith; C Bailey; J Epstein; S Yaccoby; A Hoering; J Crowley; G Morgan; B Barlogie; F van Rhee
Journal:  Blood Cancer J       Date:  2016-07-29       Impact factor: 11.037

8.  Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.

Authors:  S S Chavan; J He; R Tytarenko; S Deshpande; P Patel; M Bailey; C K Stein; O Stephens; N Weinhold; N Petty; D Steward; L Rasche; M Bauer; C Ashby; E Peterson; S Ali; J Ross; V A Miller; P Stephens; S Thanendrarajan; C Schinke; M Zangari; F van Rhee; B Barlogie; T I Mughal; F E Davies; G J Morgan; B A Walker
Journal:  Blood Cancer J       Date:  2017-02-24       Impact factor: 11.037

9.  Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.

Authors:  Brian A Walker; Christopher P Wardell; Lorenzo Melchor; Annamaria Brioli; David C Johnson; Martin F Kaiser; Fabio Mirabella; Lucia Lopez-Corral; Sean Humphray; Lisa Murray; Mark Ross; David Bentley; Norma C Gutiérrez; Ramón Garcia-Sanz; Jesus San Miguel; Faith E Davies; David Gonzalez; Gareth J Morgan
Journal:  Leukemia       Date:  2013-07-02       Impact factor: 11.528

10.  Clinical value of molecular subtyping multiple myeloma using gene expression profiling.

Authors:  N Weinhold; C J Heuck; A Rosenthal; S Thanendrarajan; C K Stein; F Van Rhee; M Zangari; A Hoering; E Tian; F E Davies; B Barlogie; G J Morgan
Journal:  Leukemia       Date:  2015-11-03       Impact factor: 11.528
View more
  25 in total

1.  Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma.

Authors:  Ilyas Sahin; Yawara Kawano; Romanos Sklavenitis-Pistofidis; Michele Moschetta; Yuji Mishima; Salomon Manier; Antonio Sacco; Ruben Carrasco; Rafael Fonseca; Aldo M Roccaro; Thomas Witzig; Irene M Ghobrial
Journal:  Blood Adv       Date:  2019-04-09

Review 2.  Molecular basis of clonal evolution in multiple myeloma.

Authors:  Yusuke Furukawa; Jiro Kikuchi
Journal:  Int J Hematol       Date:  2020-02-06       Impact factor: 2.490

Review 3.  The effect of novel therapies in high-molecular-risk multiple myeloma.

Authors:  Guido Lancman; Douglas Tremblay; Kevin Barley; Bart Barlogie; Hearn Jay Cho; Sundar Jagannath; Deepu Madduri; Erin Moshier; Samir Parekh; Ajai Chari
Journal:  Clin Adv Hematol Oncol       Date:  2017-11

Review 4.  Toward personalized treatment in multiple myeloma based on molecular characteristics.

Authors:  Charlotte Pawlyn; Faith E Davies
Journal:  Blood       Date:  2018-12-26       Impact factor: 22.113

Review 5.  Evolutionary biology of high-risk multiple myeloma.

Authors:  Charlotte Pawlyn; Gareth J Morgan
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

6.  High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.

Authors:  Anjan Thakurta; Maria Ortiz; Pedro Blecua; Fadi Towfic; Jill Corre; Natalya V Serbina; Erin Flynt; Zhinuan Yu; Zhihong Yang; Antonio Palumbo; Meletios A Dimopoulos; Norma C Gutierrez; Hartmut Goldschmidt; Pieter Sonneveld; Herve Avet-Loiseau
Journal:  Blood       Date:  2019-01-28       Impact factor: 22.113

7.  Impact of acquired del(17p) in multiple myeloma.

Authors:  Arjun Lakshman; Utkarsh Painuly; S Vincent Rajkumar; Rhett P Ketterling; Prashant Kapoor; Patricia T Greipp; Angela Dispenzieri; Morie A Gertz; Francis K Buadi; Martha Q Lacy; David Dingli; Amie L Fonder; Suzanne R Hayman; Miriam A Hobbs; Wilson I Gonsalves; Yi Lisa Hwa; Nelson Leung; Ronald S Go; Yi Lin; Taxiarchis V Kourelis; Rahma Warsame; John A Lust; Stephen J Russell; Steven R Zeldenrust; Robert A Kyle; Shaji K Kumar
Journal:  Blood Adv       Date:  2019-07-09

8.  Prognostic impact of hyperdiploidy in multiple myeloma patients with high-risk cytogenetics: a pilot study in China.

Authors:  Jiangang Mei; Yongping Zhai; Hanqing Li; Feng Li; Xiaogang Zhou; Ping Song; Qian Zhao; Yaping Yu; Zhiming An; Liping Wang
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-24       Impact factor: 4.553

Review 9.  Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Authors:  Sarah A Holstein; Zaid Al-Kadhimi; Luciano J Costa; Theresa Hahn; Parameswaran Hari; Jens Hillengass; Allison Jacob; Nikhil C Munshi; Stefania Oliva; Marcelo C Pasquini; Qian Shi; Edward A Stadtmauer; Stephanie L Waldvogel; Philip L McCarthy
Journal:  Biol Blood Marrow Transplant       Date:  2019-09-14       Impact factor: 5.742

10.  del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.

Authors:  Jill Corre; Aurore Perrot; Denis Caillot; Karim Belhadj; Cyrille Hulin; Xavier Leleu; Mohamad Mohty; Thierry Facon; Laure Buisson; Laura Do Souto; Romain Lannes; Stephanie Dufrechou; Naïs Prade; Frederique Orsini-Piocelle; Laurent Voillat; Arnaud Jaccard; Lionel Karlin; Margaret Macro; Sabine Brechignac; Mamoun Dib; Laurence Sanhes; Jean Fontan; Lauriane Clement-Filliatre; Jean-Pierre Marolleau; Stephane Minvielle; Philippe Moreau; Hervé Avet-Loiseau
Journal:  Blood       Date:  2021-03-04       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.